Human Longevity Oncology Division Sold to NeoGenomics for $37 Million

Transaction supports the company’s focus and refinement of its longevity platform to grow commercial adoption in both US and international markets

SAN DIEGO--(BUSINESS WIRE)--Human Longevity, Inc., an innovator in providing data-driven health intelligence and precision health to physicians and patients announced today that the Oncology Division was sold to NeoGenomics (NASDAQ NEO) for $37 Million. The financing, a cash transaction, closed on Friday, January 10, 2020.

David Karow, MD, PhD, President and Chief Innovation Officer of Human Longevity, Inc., said, “The sale of this division allows us to focus entirely on longevity and extending the healthy, high-performance human lifespan. Additionally, it will provide the firm with additional working capital, along with the recent Series A2 round of financing, to grow domestically and internationally.”

ABOUT HUMAN LONGEVITY

Human Longevity provides unparalleled, precision health analytics to individuals through the Health Nucleus in La Jolla, CA. The Health Nucleus provides an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. This is provided via a multi-modal approach, integrating data from an individual’s whole genome, brain and body imaging via MRI, cardiac CT calcium scan, metabolic tests and more, using machine learning and artificial intelligence.